RxDoctor Payments Data

David Bilstrom

Portland, ORNPI 1790766764

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,241 of the $6,436 with a category attached, or 65.9%. 21 manufacturers reported payments, led by Pfizer at 39.4% of the total. Reporting peaked in 2019 at $2,615 and has fallen 88.8% since, to $292 in 2023.

$6,436in general payments, 2019–2025

Across 202 payments — averaging $31.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$3K
  • AstraZeneca$851
  • GSK$463
  • Takeda Pharmaceuticals U.S.A., Inc.$433
  • Regeneron Healthcare Solutions, Inc.$340
  • CSL Behring$257
  • plus $2K from 15 others

What the payments were for

  • Speaking & faculty fees$2,08032%
  • Food & beverage$4,24166%
  • Education$1162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →